Search
Results: 5
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
Josée M Zijlstra, George Follows, Rene-Olivier Casasnovas, Joost SP Vermaat, Nagesh Kalakonda, Sylvain Choquet, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan-Manuel Sancho, Michael Schuster, Miklos Egyed, Fritz Offner, Theodoros P Vassilakopoulos, Priyanka Samal, Matthew Ku, Jenny Xu, Kelly Corona, Kamal Chamoun, Jatin Shah, Miguel Canales, Marie Maerevoet
Feb 05, 2022
Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc...
Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.
Peifeng Li, Jia Chai, Zi Chen, Yang Liu, Jie Wei, Yixiong Liu, Danhui Zhao, Jing Ma, Kaijing Wang, Xia Li, Yang Shao, Li Gong, Wei Zhang, Shuangping Guo, Qingguo Yan, Mingyang Li, Linni Fan, Zhe Wang
Mar 19, 2021
Primary gastrointestinal diffuse large B-cell lymphoma (GI-DLBCL) is the most common gastrointestinal lymphoma, but its genetic features are poorly understood. We performed whole-exome sequencing of 25 primary tumor samples from...
The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.
Josée M Zijlstra, George Follows, Rene-Olivier Casasnovas, Joost SP Vermaat, Nagesh Kalakonda, Sylvain Choquet, Brian Hill, Catherine Thieblemont, Federica Cavallo, Fatima De la Cruz, John Kuruvilla, Nada Hamad, Ulrich Jaeger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan-Manuel Sancho, Michael Schuster, Miklos Egyed, Fritz Offner, Theodoros P Vassilakopoulos, Priyanka Samal, Matthew Ku, Jenny Xu, Kelly Corona, Kamal Chamoun, Jatin Shah, Miguel Canales, Marie Maerevoet
Mar 18, 2022
Selinexor, an oral selective inhibitor of nuclear export, was evaluated in the Phase 2b SADAL study in patients with diffuse large B-cell lymphoma (DLBCL) who previously received two to five prior systemic regimens. In post hoc...
Molecular profiling in diffuse large B-cell lymphoma
The term diffuse large B-cell lymphoma (DLBCL) includes a heterogeneous collection of biologically distinct tumours. This heterogeneity currently presents a barrier to the successful deployment of novel, biologically targeted...
FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.
Kah Keng Wong, Duncan M Gascoyne, Elizabeth J Soilleux, Linden Lyne, Hayley Spearman, Giovanna Roncador, Lars M Pedersen, Michael B Møller, Tina M Green, Alison H Banham
Dec 17, 2018
FOXP2 shares partially overlapping normal tissue expression and functionality with FOXP1; an established diffuse large B-cell lymphoma (DLBCL) oncogene and marker of poor prognosis. FOXP2 is expressed in the plasma cell...
FOXP2 diffuse large B-cell lymphoma survival Adult Aged Aged 80 and over Antibodies Monoclonal Murine-Derived Antineoplastic Combined Chemotherapy Protocols Cell Line Tumor cyclophosphamide Doxorubicin Female Forkhead Transcription Factors Gene Expression Profiling Gene Expression Regulation Neoplastic Gene Ontology Humans Kaplan-Meier Estimate Lymphoma Large B-Cell Diffuse Male Middle Aged prednisone Protein Binding Repressor Proteins Signal Transduction Transcriptome Vincristine Young Adult